WASHINGTON, Jan. 13, 2009 (GLOBE NEWSWIRE) -- Finkelstein Thompson LLP is currently investigating potential shareholder claims for breach of fiduciary duty in connection with the proposed purchase of Advanced Medical Optics, Inc. ("Advanced Medical") (NYSE:EYE) by Abbott Laboratories ("Abbott Labs") (NYSE:ABT). Under the agreement announced today, Abbott Labs will pay roughly $1.36 billion and will assume certain debts, bringing the total value of the deal to approximately $2.8 billion. This represents a 12% discount from the Company's 52-week high of $24.90.
The investigation is focused on the sufficiency of the merger consideration, the adequacy of the disclosures, and the fairness of the deal-protection provisions of the merger agreement. If you are interested in discussing your rights as an Advanced Medical shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com.